A CLINICALLY AND ECONOMICALLY PROVEN SOLUTION
Driven by advanced technology and backed by key clinical data, the Starling system provides accurate and reliable fluid monitoring with real-time, continuous measurement of stroke volume and other critical parameters. The vital information provided by the Starling system enables clinicians to make therapy decisions that help improve patient outcomes and reduce the total cost of care.
PROPER FLUID MANAGEMENT MAY IMPROVE CLINICAL OUTCOMES AND REDUCE COSTS
80% of hospital patients receive IV fluid therapy as a routine part of treatment.1 Yet studies show that administering too much or too little fluid can lead to serious complications and contribute to rising healthcare costs.2-3
Improper fluid management is associated with higher:
- Length of stay2,3
- Ventilator usage2,3
- Acute dialysis2
- Total hospitalization costs2,3
SUPPORTING SEP-1 BUNDLE COMPLIANCE
With fluids acting as the first line of treatment for sepsis, the Starling system plays a critical role in the management of septic patients. The Starling system is the only device to demonstrate improved patient outcomes when a dynamic assessment of fluid responsiveness is used to guide fluid administration in the septic patient population.
The PLR technique translocates 250-300 cc of blood from lower extremities into the heart, providing reversible challenge of the heart’s response to increased fluid load. The Starling system’s non-invasive monitoring technology provides real-time assessment of a patient’s fluid responsiveness.
In a retrospective, matched, single-center study, researchers from the University of Kansas Health System evaluated stroke volume (SV) guided resuscitation in 100 ICU patients with severe sepsis and septic shock.4,5
DAYS reduced length of stay in ICU
REDUCED risk of mechanical ventilation
REDUCED initiation of acute dialysis
SAVINGS per treated patient
We embarked on this study with the hypothesis that actively managing patients’ fluids was associated with improved clinical outcomes. The study demonstrated positive patient outcomes from actively monitoring resuscitation by optimizing stroke volume, which may be translated to significant cost savings to the hospitals caring for these very critical patients.
Dr. Heath Latham, University of Kansas Health System
REDUCING SECONDARY INTERVENTIONS THROUGH IMPROVED OUTCOMES
Backed by the FRESH (Fluid Responsiveness Evaluation in Sepsis-associated Hypotension) Trial, the Starling system is the only device to show proven outcomes via dynamic assessment in sepsis patients through a randomized, controlled study.6
Conducted among 124 patients across 13 hospital facilities, the FRESH Trial met its primary endpoint of significantly lower fluid balance at 72 hours or ICU discharge. It also demonstrated statistically significant outcomes in reduced initiation of mechanical ventilation and renal replacement therapy.
Rx only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator's Manual or Instructions for Use.
Baxter, Starling and Bioreactance are trademarks of Baxter International Inc. or its subsidiaries.